All marketing authorization holders of medicine are hereby informed that NMRA decided not to register new products or not to renew existing products of Ramipril Modified Release dosage forms as Ramipril has a long half-life which anyway allows for once daily dosing and there is no particular advantage of having a modified release dosage form.